THE 30STARTUPS OF KANSAI

AIBTRUST Inc. is a deep tech company born from Osaka University research, building the trust infrastructure that lets medical data circulate safely and legally. Founded in Osaka in 2023, we return ownership of clinical records from hospitals to patients, who then grant or refuse consent, case by case, from their smartphone. Two products make this real: Health Interview, an AI-powered SaaS that digitizes hospital operations, and Medireco, the patient app holding both the data and the consent. Backed by proprietary patents, joint research with Osaka University Hospital, 300 million yen from Osaka University Venture Capital, and METI’s Go-Tech program.

Medical records sit locked inside individual hospitals. Patients cannot reach their own data; researchers cannot use it because privacy law restricts third-party disclosure; and when that data creates value, none of it returns to the patients or hospitals it came from. AIBTRUST solves all three at once. Patients view their test results, images and prescriptions on their phone. Hospitals automate more than 60% of routine workflows with generative AI and gain a new, risk-free revenue stream. Researchers and pharmaceutical companies finally reach consented, high-quality real-world data, shortening the path to new treatments.

Most players try to anonymize data. We move the legal ownership instead. Under Japan’s Medical Care Act provision for returning records to patients, the patient, not the hospital, becomes the data holder, so consent becomes lawful and immediate. The raw data never leaves the hospital: only a cryptographic key, issued as an NFT usage-right token, travels. A smart contract records every consent immutably, creating the audit trail that FDA GMLP and the EU AI Act now demand, and instantly distributes payment. Protected by patent (JP 7498999), with no equivalent implementation in Japan.

By 2030 we intend to make patient-owned data circulation a global standard, starting from Japan. In the near term we are scaling Health Interview across hospitals and clinics to build a next-generation clinical registry, then opening a marketplace where pharmaceutical and medical device companies purchase consented real-world data and the proceeds flow back to patients and hospitals. Japan’s strict privacy regime makes it the hardest market to solve, and the strongest proof point. We now seek global partners and investors to carry this model into Asia, Europe and the United States.